Test vitamin E plus two cancer drugs for metastatic colon cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests whether adding vitamin E to two cancer medicines (fruityquintinib and tislelizumab) can work better in people with metastatic colorectal cancer that is mismatch-repair stable (MSS). It may help if your cancer has grown despite standard treatment, and you can meet the study’s safety and blood/organ requirements.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be age 18 or older, and have colorectal cancer that cannot be fully removed and has spread
- Your cancer should be MSS or microsatellite stable (not MSI-H or dMMR) based on tumor testing
- Your cancer must have grown during or after standard chemotherapy, or you could not tolerate it
- You must not have had prior immune therapy that blocks PD-1, PD-L1, or CTLA-4
- You must have at least one measurable tumor spot on scans, and good basic health (ECOG 0–1)
- Blood tests and organ function must be within study limits (for things like white blood cells, platelets, liver, and kidney)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of two immunotherapy drugs (iparomlimab and tuvonralimab) with standard chemotherapy and a targeted therapy (cetuximab) as the first treatment for colorectal cancer that has come back or spread. The goal is to see if this combination can shrink tumors and help patients live longer.
This trial tests a new combination of ultra-precise radiation therapy, immunotherapy, chemotherapy, and targeted therapy for people with metastatic colorectal cancer that has a normal DNA mismatch repair system. The goal is to see if this personalized approach can better control the cancer and improve outcomes.
This trial tests a combination of two drugs (fruquintinib and adebrelimab) plus low or high dose radiation for people with advanced colorectal cancer that has not responded to standard treatments. The goal is to see if this combination can shrink tumors or slow the disease.
This trial tests a combination of two targeted drugs (cetuximab beta and fruquintinib) with or without an immunotherapy drug for people with a specific type of advanced colorectal cancer that has not been treated before. It aims to see if this approach is safe and effective for those whose tumors have certain genetic markers (RAS and BRAF wild type).
This trial tests a combination of three drugs (fruquintinib, chidamide, and sintilimab) for people with a specific type of metastatic colorectal cancer that has not responded to at least two prior treatments. It aims to see if this combination is safe and effective.
This study tests a combination of precisely targeted radiation (SBRT) with two drugs: fruquintinib (a pill that blocks blood supply to tumors) and antibodies that boost your immune system to fight cancer (PD-1 and CTLA-4 inhibitors). It is for people with advanced colorectal cancer who have already tried two standard chemotherapy treatments.
Hear when a new Colorectal cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.